Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase vs Alteplase in Asian AMI Patients
NCT00148460Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2001
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in acute myocardial infarction (AMI) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Thrombolysis in Myocardial Infarction Grade 3 Flow. Started Mar 2001; status: completed.
02
Drugs
tenecteplase
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT00148460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148460.